| IMMUNITYBIO INC. DL-,0001 |
| USA |
| Gesundheit |
| US45256X1037 / A2QQ2E |
| 26CA (Frankfurt) / IBRX (NASDAQ) |
| FRA:26CA, ETR:26CA, 26CA:GR, NASDAQ:IBRX |
| - |
| https://immunitybio.com/ |
|
ImmunityBio, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing next-generation immunotherapies that harness the body's innate and adaptive immune systems to combat cancer and infectious diseases. Its lead pr..
>Volltext.. |
| 7215.79 Mio. EUR |
| 7862.82 Mio. EUR |
| 121.41 Mio. EUR |
| -211.26 Mio. EUR |
| -735.92 Mio. EUR |
| -0.74 EUR |
| 968.5 Mio. EUR |
| 176.71 Mio. EUR |
| - |
| 5.61 |
| 322.8% |
| -95.59% |
| - |
| - |
| - |
| - |
| IMMUNITYBIO |
| 20.05.26 |
|